Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Emergent Biosolutions Inc before investing.
In this article, we go over a few key elements for understanding Emergent Biosolutions Inc’s stock price such as:
- Emergent Biosolutions Inc’s current stock price and volume
- Why Emergent Biosolutions Inc’s stock price changed recently
- Upgrades and downgrades for EBS from analysts
- EBS’s stock price momentum as measured by its relative strength
About Emergent Biosolutions Inc
(EBS)
Before we jump into Emergent Biosolutions Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Want to learn more about Emergent Biosolutions Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Emergent Biosolutions Inc.
What Caused Emergent Biosolutions Inc Stock’s Price to Dip?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 30, 2024, there was 1 analyst who downgraded Emergent Biosolutions Inc’s stock and 0 analysts who upgraded over the last month.
Additionally, you'll want to evaluate Emergent Biosolutions Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Emergent Biosolutions Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Emergent Biosolutions Inc’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Emergent Biosolutions Inc
(EBS) by visiting AAII Stock Evaluator.
Relative Price Strength of Emergent Biosolutions Inc
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of August 30, 2024, Emergent Biosolutions Inc has a weighted four-quarter relative price strength of 23.72%, which translates to a Momentum Score of 95 and is considered to be Very Strong.
Want to learn more about how Emergent Biosolutions Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
Emergent Biosolutions Inc Stock Price: Bottom Line
As of September 3, 2024, Emergent Biosolutions Inc’s stock price is $7.39, which is down 11.07% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Emergent Biosolutions Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Included With AAII Platinum
Screen: 23.7%
Annual Gain Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.